NEW YORK, NY — OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced that the first patient has been dosed in the Phase 1 study evaluating CUSP06 for the treatment of platinum-refractory/resistant ovarian cancer and...
Latest News
PARIS — One Biosciences, a biotech company leveraging the power of single-cell analysis and A.I. to identify a new generation of precision medicine targets and treatments, announced today a partnership with Assistance Publique – Hôpitaux de Paris (AP-HP), a consortium of nearly all hospitals in the greater Paris region, to...
ORLANDO, Fla.–The vast majority of advanced colon cancer patients in a clinical trial were not concerned about the cost of prescription drugs for managing chemotherapy side effects, such as infection, pain and nausea and few adopted strategies to reduce drug cost burdens after joining the clinical trial, according to a...
BUFFALO, NY – A new editorial paper was published in Oncotarget’s Volume 14, entitled, “One more step toward treatment of PARP inhibitor-resistant ovarian cancers.” Over 80% of ovarian cancer cases experience recurrence, resulting in roughly 12,000 annual deaths in the United States. While targeted therapies like poly (ADPribose) polymerase inhibitors...
Tel Aviv, Israel – In a first, Tel Aviv University researchers have discovered that the production and regulation of mitochondrial organelles in the brain’s nerve cells (neurons) becomes significantly impaired with the deletion of a gene called Gtf2i, one of the 25 genes deleted in Williams syndrome. This impairment is...
Basel — New results from a one-year Phase III study have confirmed that the investigational biological therapy Ilaris® (canakinumab, formerly ACZ885)[*] produced rapid and sustained remission of symptoms in the majority of children and adults with a rare and potentially life-threatening auto-inflammatory disease called cryopyrin-associated periodic syndrome (CAPS)[1],[2],[3]. The study...
An online symptom management tool that harnesses the problem-solving benefits of expressive writing could help women with ovarian cancer better manage complex symptoms, according to a new study led by a University of Pittsburgh and UPMC nurse-scientist. Published today in the Journal of Clinical Oncology, the study found that patients...
Hattie Foster looks up to the sky. She’s 6 years old. The sun is shining, and she’s buzzing with energy. “Where’s the moon?” she asks whomever is listening. Her older brother, 9-year-old Charlie, climbs across the nearby jungle gym at a Prairie Village playground as her younger brother, 3-year-old Will,...
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive lymphoma with no approved treatment in the U.S.1 In the Phase 2 PROSPECT Study, tirabrutinib demonstrated an overall response rate of 67%, complete response rate of 44%, and a manageable safety profile2 OSAKA, Japan — Ono Pharmaceutical Co., Ltd. (Headquarters:...
OSAKA, Japan — Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) announced that efficacy signals for ONO-2808, a S1P5 receptor agonist, were observed in the interim analysis of the Phase 2 clinical trial (ONO-2808-03 study) which assessed the safety and efficacy of ONO-2808 compared to...